Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
T. J. A. Allen
Observed names:
T Allen,
T.J. Allen
Institutions:
Novartis (Switzerland),
The University of Melbourne
Observed institutions:
Novartis (Switzerland),
The University of Melbourne
OpenAlex ID:
A5018241538
Direct anti-atherogenic properties of PPAR alpha and PPAR gamma agonists
2005
·
ME Cooper
, Forbes Jm
, et al.
·
1
Does combined blockade of RAS and advanced glycation end-product formation confer superior renoprotection in a hypertensive model of diabetic nephropathy?
2002
·
BJ Davis
, Forbes Jm
, et al.
·
1
Th-P16:287 Rosiglitazone and gemfibrozil mediate lipid and glucose independent anti-atherogenic and renoprotective actions in a model of experimental diabetes
2006
·
A.C. Calkin
, S. Giunti
, et al.
·
Atherosclerosis Supplements
Inhibitors of advanced glycation end product accumulation ameliorate renal injury in the diabetic apoE knockout mouse
2004
·
K. Jandeleit-Dahm
, Markus Lassila
, et al.
Attenuation of diabetes associated atherosclerosis with the advanced glycation end product cross-link breaker, ALT-711
2003
·
T. J. A. Allen
, Forbes Jm
, et al.
1P-0273 Attenuation of diabetes-associated atherosclerosis with the advanced glycation end product cross-link breaker, ALT-711
2003
·
A.C. Calkin
, L.T.L. Yee
, et al.
·
Atherosclerosis Supplements
Effect of combination therapy (ANG II antagonist, valsartan and a calcium channel blocker) in a hypertensive model of diabetic nephropathy
2000
·
T Allen
·
American Journal of Hypertension
Pharmacologic treatment of early diabetic nephropathy
1994
·
George Jerums
, T. J. A. Allen
, et al.
·
Nefrología
Show more works
View as search
Works count:
8
Citation count:
2
H-index:
1
I10-index:
Year
Topic
Type